Core Faculty Member at the Broad Institute, Dana-Farber Cancer Institute, and Harvard Medical School
Dr. Sellers recently joined the faculty at the Broad Institute of MIT and Harvard, the Dana-Faber Cancer Institute (DFCI), and Harvard Medical School Broad, where he is launching a new research group. Previously, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for BioMedical Research from 2005-2016. Since joining Novartis the oncology research group brought more than 30 small molecule, biologic and cell-based cancer therapeutics into first-in-human trials including drugs targeting the PI3K, CDK4, IDH, ABL, SMO, HER3, ALK, Wnt, PIM and Ras pathways among many others. Since 2014 he also directed the Translational Clinical Oncology (TCO) organization which oversaw the early clinical development of molecules in human proof-of-concept trials.
He previously was an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute. Dr. Sellers is a member of the National Cancer Advisory Board and serves on the Scientific Advisory Board for the Caring for Carcinoid Foundation. Dr. Sellers received his B.S. from Georgetown University in 1982 and M.D. from the University of Massachusetts Medical School in 1986. He completed residency training in Internal Medicine at the University of California San Francisco in 1989 and trained in Medical Oncology at the Dana-Farber Cancer Institute.